LDI has been used successfully to treat a variety of cancers without causing significant symptoms or incurring significant risk. Evidence suggests that LDI therapy can slow or reverse tumor growth and prevent metastases. Given the high prevalence of breast and prostate cancer, and evidence of LDI efficacy in other cancers, controlled studies of LDI in breast or prostate cancer are suggested. Monitoring of specific tumor markers in the blood, such as PSA, and CT images, would provide an early indication of regression or lack thereof. LDI therapy appears to be a promising complement or option in treatment of cancer, based upon the hormesis effect. The information about the relative risks and benefits of this therapy should be publicized widely, so patients and their physicians can make informed choices about optimal treatment options.

Reprinted with Permission from www.jpands.org and www.aapsonline.org

Journal of American Physicians and Surgeons Volume 8 Number 4 Winter 2003